Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Elijah Owens

Neurology Florence, SC Medical Doctor

NPI 1417156886 CMS profile 154583

1594 Freedom Blvd, Suite 305, Florence, SC 29505

Open in the dashboard

General payments

$4,927

251 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Elijah Owens of Florence, SC is reported in the CMS Open Payments database as having received $4,927 across 251 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $38 1
2023 General $2,199 105
2022 General $1,424 70
2020 General $37 3
2019 General $1,228 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elijah Owens
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Elijah Owens were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Elijah Owens Neurology median Middle half National median
2019 $1,228 $474 $118–$2,177 $163
2020 $37 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $1,424 $442 $103–$2,388 $149
2023 $2,199 $464 $119–$2,312 $160
2024 $38 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. UCB, Inc. $581 23 payments
  2. Biogen, Inc. $516 25 payments
  3. Novartis Pharmaceuticals Corporation $488 25 payments
  4. SK Life Science, Inc. $344 18 payments
  5. Genzyme Corporation $230 12 payments
  6. Teva Pharmaceuticals USA, Inc. $207 12 payments
  7. Celgene Corporation $196 11 payments
  8. Neurocrine Biosciences, Inc. $181 7 payments
  9. Genentech USA, Inc. $181 12 payments
  10. Alexion Pharmaceuticals, Inc. $170 9 payments
  11. Other $1,833 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $4,915 250 payments
  2. Education $11 1 payment
Products named General payments · program years 2019–2024
  1. TYSABRI $407 19 payments
  2. VUMERITY $398 18 payments
  3. Briviact $338 13 payments
  4. AIMOVIG $198 10 payments
  5. ZEPOSIA $196 11 payments
  6. APTIOM $194 11 payments
  7. INGREZZA $181 7 payments
  8. Ongentys $181 7 payments
  9. OCREVUS $181 12 payments
  10. KESIMPTA $148 7 payments
  11. Other $2,855 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 80 drugs

Part D claims

5,426

Median for Neurology: 833

Drug cost

$2,279,568

Median for Neurology: $202,670

Branded share of claims

25.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 69 $667,934
Copaxone Glatiramer Acetate Brand 23 $169,493
Nuplazid Pimavanserin Tartrate Brand 29 $153,025
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 19 $140,327
Austedo Deutetrabenazine Brand 14 $127,107
Betaseron Interferon Beta-1b Brand 13 $112,130
Emgality Pen Galcanezumab-Gnlm Brand 72 $107,587
Aimovig Autoinjector Erenumab-Aooe Brand 63 $103,546
Plegridy Pen Peginterferon Beta-1a Brand 12 $97,032
Ingrezza Valbenazine Tosylate Brand 12 $74,615

The 10 drugs with the highest cost, of 80 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$170,175

Medicare's payments for the services billed

Medicare patients

851

Average age 72

Services billed

2,643

463 women, 388 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 43%
Ischemic heart disease 33%
Chronic kidney disease 33%
Depression 33%
Heart failure 30%
Alzheimer's or dementia 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record